- Country: USA
- Summary: Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
- UST Ref No: 73665967
- Deadline: 14 Dec 2022
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: Ht9402-23-Q-9101
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: February 2023: The following drug classes/subclass will be reviewed:
a. Androgens-Anabolic Steroids - Subclass: Testosterone Replacement Therapies Androderm Jatenzo Kyzatrex Methitest Natesto Testim Tlando Xyosted b. Sleep Disorders - Subclass: Dual Orexin Receptor Antagonists Belsomra Dayvigo Quivivq
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-23-Q-9101.
Pre-proposal teleconference is on November 9, 2022, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the... - Documents:
Appendix-Androgens-Anabolic-Steroids-Testosterone-Replacement-Therapies.xlsx
Appendix-Sleep-Disorders-Dual-Orexin-Receptor-Antagonists.xlsx
February-2023-P-and-T-Meeting-Reporting.xlsx
Price-Appendix-FAQ-Class-Review.pdf
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINDepartment of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program - USA Tender
The DEPT OF DEFENSE, a Government sector organization in USA, has announced a new tender for Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program. This tender is published on USARFP under UST Ref No: 73665967 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2022-12-14.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
